Librela for Dogs: Side Effects & Safety

Librela (bedinvetmab injection), made by Zoetis, was FDA-approved in May 2023 as a monthly injection to manage osteoarthritis (OA) pain in dogs — the first monoclonal antibody drug approved for this use in the United States. It works by blocking Nerve Growth Factor (NGF), a protein involved in chronic joint pain signaling. By December 2024, the FDA’s Center for Veterinary Medicine had received enough adverse event reports to issue a formal “Dear Veterinarian” letter — a significant regulatory action alerting the veterinary community to serious safety signals including neurological events and musculoskeletal concerns. Zoetis has since updated the drug’s label. Here is what the science and the FDA actually say.

• 1
  What are the negative side effects of Librela in dogs? The FDA identified serious adverse events including ataxia (unsteady gait/wobbliness), seizures, paresis (partial paralysis), hind leg weakness, urinary incontinence, excessive thirst and urination, and in some cases death including euthanasia. Milder side effects include lethargy, vomiting, and loss of appetite.

  In December 2024, the FDA’s Center for Veterinary Medicine issued a formal “Dear Veterinarian” letter after evaluating 3,674 adverse drug event reports (received from Librela’s approval in May 2023 through April 2024). The adverse events identified and analyzed include: ataxia, seizures, other neurological signs including paresis (partial paralysis), recumbency (inability to stand), urinary incontinence, polyuria (frequent urination), and polydipsia (excessive thirst). In some cases, death including euthanasia was reported as an outcome. Per the AVMA (February 2025): two-thirds of adverse event reports indicated clinical signs occurring within the first week after administration, with 30% occurring within the first day. Signs were observed after the initial dose in 70% of reported cases.
• 2
  How long do Librela side effects last? It depends on the severity. Mild side effects (lethargy, GI upset) often resolve within days to a week. Serious neurological side effects may persist longer because Librela has a half-life of approximately 19 days — meaning the drug remains active in your dog’s body for 5–8 weeks after an injection.

  This is one of the most important pharmacological facts about Librela: unlike a pill that clears the body in hours, a monoclonal antibody injection has a prolonged half-life. According to the Canadian product insert and veterinary pharmacology data, Librela’s half-life averages approximately 19 days. That means 50% of the drug is gone in 19 days and 75% in 38 days — but it takes roughly 5–8 weeks for the drug to largely clear the system. This matters critically for serious side effects: if your dog has a severe neurological reaction, supportive care may be required for weeks while the drug gradually clears. Seattle Veterinary Associates (December 2025) notes that if a dog has received multiple doses without problems, the side effects do not appear to be cumulative — suggesting that dogs who will react tend to react early rather than after months of use.
• 3
  Will Librela side effects go away on their own? Mild side effects usually resolve on their own within days to weeks as the drug clears. Serious neurological side effects may require supportive veterinary care. Because the drug cannot be removed after injection, there is no antidote — only waiting and supportive treatment.

  Seattle Veterinary Associates confirms that the vast majority of reported side effects were mild and resolved on their own, and that adverse effects do not appear to be cumulative. However, for dogs experiencing serious neurological reactions (seizures, paralysis, inability to stand), the situation is more complex. Canine Arthritis Resources and Education (CARE, June 2025) notes that the drug’s half-life means that if your dog is sensitive to its adverse effects, the drug will continue circulating for weeks. Once injected, it cannot be extracted. Veterinary supportive care (fluids, anti-seizure medications, nursing care) may be necessary during that period. Any dog that experiences a significant reaction to Librela should not receive it again — per official contraindication guidance from CARE and Zoetis.
• 4
  Can Librela cause hind leg weakness or neurological problems? Yes — hind leg weakness (ataxia) is one of the most commonly reported serious adverse events linked to Librela. The FDA identified neurological signals including ataxia, seizures, paresis, and proprioceptive deficits as priority concerns in its official adverse event analysis.

  The FDA’s CVM adverse event report (through March 2024) specifically identified neurological signals as among the 18 distinct safety signals found in dogs receiving Librela, based on disproportionality analysis comparing Librela to other osteoarthritis medications. The Drake Center for Veterinary Care (AAHA-accredited) confirmed that of the 363 cases included in the FDA’s detailed neurological case series evaluation, ataxia (unsteadiness, particularly of the hind legs) was the most commonly reported serious adverse effect alongside lethargy and anorexia. The CARE organization (June 2025) notes that 73% of neurological adverse event cases involved dogs over 10 years old — an age group already at higher risk for underlying degenerative neurological conditions. Frontiers in Veterinary Science (Farrell et al., 2025, peer-reviewed) also found an 18-member expert panel unanimously concluded a strong suspicion of causal association between Librela and accelerated joint destruction in 19 reviewed cases.
• 5
  What dogs should not get Librela? Librela is contraindicated in: pregnant, nursing, or breeding dogs (including male dogs used for breeding), puppies under 12 months old, and any dog with a known hypersensitivity to bedinvetmab. Extra caution is advised in dogs over 10 with underlying neurological conditions.

  Zoetis Petcare’s official FAQ states directly: “Librela should not be used in breeding, pregnant, or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab.” The Canine Rehab OC veterinary practice (October 2025) adds that Librela should not be used in physically immature dogs — noting that many large or giant-breed dogs do not reach physical maturity until 2–3 years of age, not just 12 months. The FDA’s official labeling explicitly states: “The safety and effectiveness of Librela has not been evaluated in dogs less than 12 months of age.” The CARE organization (June 2025) also notes that any dog that has had a reaction to Librela should not receive it again, and that there are no studies of Librela’s long-term effects beyond 9 months of use — a critical knowledge gap. Librela has not been studied in dogs with a history of cruciate ligament rupture within six months prior to starting treatment.
• 6
  Is Librela worth the risk? For many dogs with debilitating arthritis pain — especially those who cannot tolerate NSAIDs — the benefit may outweigh the risk. For others, the risk-benefit calculus is less clear. This decision requires an honest conversation with your veterinarian based on your dog’s specific health history.

  Zoetis reports approximately 25 million doses distributed globally and states that serious adverse events occur in roughly 0.1% of dogs receiving the medication — a rate Zoetis considers rare. Seattle Veterinary Associates (December 2025) confirms this rate. However, CARE (June 2025) and Frontiers in Veterinary Science (Farrell et al., 2025) raise a more serious concern: a 2025 peer-reviewed study found that ligament/tendon injuries, polyarthritis, fractures, musculoskeletal neoplasia, and septic arthritis were reported approximately nine times more frequently in Librela-treated dogs than in dogs treated with all comparator OA drugs combined. The Drake Center notes Librela remains valuable for dogs with limited other options — particularly those who cannot tolerate NSAIDs due to kidney disease, liver disease, or GI sensitivity. Austin Canine Rehab (July 2025) emphasizes Librela is most appropriate as a later option after other interventions, not a first-line treatment.
• 7
  What are Librela’s long-term side effects? Long-term effects beyond 9 months have not been formally evaluated. Emerging concerns include potential for Rapidly Progressive Osteoarthritis (RPOA) — accelerated joint destruction — which has been reported in some dogs and matches a serious safety signal seen in humans with anti-NGF drugs.

  The FDA’s official labeling states explicitly: “Long-term effects which may occur more than 9 months after the use of Librela have not been evaluated.” This is a significant knowledge gap. The most serious emerging long-term concern is Rapidly Progressive Osteoarthritis (RPOA) — a phenomenon where joint disease actually accelerates rather than improves. This is not hypothetical: anti-NGF drugs in humans were halted by the FDA between 2010 and 2012 specifically due to significant reports of RPOA and osteonecrosis (bone death) in human patients. As of August 2025, RPOA is being investigated in dogs on Librela. Farrell et al. (Frontiers in Veterinary Science, May 2025) published a peer-reviewed case series of 19 dogs showing suspected worsening of joint disease following Librela, with dramatic bony proliferation and joint dislocation. The mechanism may involve NGF’s role in joint proprioception — by reducing pain signals, dogs may overuse damaged joints without realizing it.
• 8
  What is panting as a side effect of Librela? Increased panting (along with increased thirst and urination) is among the milder but frequently reported side effects noted by dog owners using Librela. These signs can indicate discomfort, a stress response, or a systemic reaction to the drug.

  While panting is not specifically listed in the FDA’s formal adverse event categories, CARE (June 2025) and community reports gathered through the Librela Experiences Facebook group document increased panting, excessive thirst, and increased urination as commonly reported experiences even in dogs who are otherwise tolerating Librela. The official Canadian product insert — generally considered more comprehensive in its adverse event listings than the U.S. label — includes a broader range of systemic signs. Polydipsia (excessive thirst) and polyuria (frequent urination) are explicitly listed in the FDA-recognized adverse event profile following post-approval reporting. Any new or unusual behavior after a Librela injection — including new-onset panting, restlessness, or changes in thirst — should be noted and reported to your veterinarian, particularly within the first week after dosing.
• 9
  What are the side effects of stopping Librela for dogs? Stopping Librela does not cause withdrawal effects in dogs. Pain relief from Librela gradually diminishes over the 4-week dosing interval as the drug clears. Dogs may experience a return of arthritis pain, but there are no known stopping-related adverse effects.

  Unlike many pain medications, there is no evidence of withdrawal or rebound effects from stopping Librela. Because it is a monthly injectable monoclonal antibody rather than a daily oral medication, the transition out of the system is gradual (half-life of approximately 19 days). The practical reality: if your dog has been receiving pain relief from Librela and injections stop, arthritis pain is likely to gradually return over the weeks following the last dose as drug levels decline. The CARE organization (June 2025) recommends that dogs who experience any reaction to Librela should not receive it again and that alternative pain management options should be discussed with a veterinarian. These alternatives include NSAIDs (Rimadyl/carprofen, Metacam/meloxicam, Galliprant/grapiprant), gabapentin, and Adequan, depending on the individual dog’s health profile.
• 10
  How does Librela work and why does it cause neurological effects? Librela blocks Nerve Growth Factor (NGF), a protein involved in pain signaling. NGF, however, also plays roles throughout the nervous system, heart, and musculoskeletal tissue — which is why blocking it systemically can affect systems beyond the joints.

  NGF is not exclusively a pain signal. As the FDA’s labeling notes, “NGF is expressed within the heart and vasculature” and is involved in the normal development of sensory and sympathetic nerve fibers. By binding to and blocking NGF throughout the body (not just in arthritic joints), Librela’s effects are systemic. The Frontiers in Veterinary Science global pharmacovigilance study (Monteiro et al., 2025) and the musculoskeletal adverse events study (Farrell et al., 2025) both note that the mechanism linking Librela to neurological events may involve reduced proprioception (the nervous system’s ability to sense joint position) and direct effects on nerve tissue. Primate studies included in the FDA labeling found anatomical changes in postganglionic nerve cell bodies at high doses — though these changes reversed after the drug was stopped. Seattle Veterinary Associates (December 2025) confirms that the theoretical cardiac concern (NGF is present in heart cells) has not been confirmed in clinical data as of their December 2025 review.

Sources: FDA CVM Dear Veterinarian Letter Dec 2024 (fda.gov; 3,674 adverse event reports; ataxia, seizures, paresis, recumbency, urinary incontinence, polyuria, polydipsia, death/euthanasia; 18 distinct safety signals; disproportionality analysis); AVMA News Feb 2025 / JAVMA print edition (2/3 events within first week; 30% within first day; 70% after first dose); AAHA Librela label update Feb 2025 (Zoetis label revision; adverse event categories; client information sheet); AAHA FDA adverse events Jan 2025 (Zoetis CMO Goldstein statement; contraindications); Frontiers in Veterinary Science Farrell et al. May 2025 PMID:40417367 (19 dogs accelerated joint destruction; expert panel causal association; ligament/tendon 9x more frequent); Frontiers in Veterinary Science Monteiro et al. 2025 (global pharmacovigilance; 18 safety signals); Zoetis Petcare FAQ (contraindications; 0.1% serious adverse event rate; 25M doses; label update); CARE Canine Arthritis Resources and Education Jun 2025 (half-life 19 days; 73% cases dogs >10yo; RPOA concern Aug 2025; no drug again after reaction); Seattle Veterinary Associates Dec 2025 (effects not cumulative; cardiac no current evidence; 0.1% rate); Austin Canine Rehab Jul 2025 (last resort not first line); Drake Center AAHA-accredited (ataxia most common neurological; older dogs predisposed); Canine Rehab OC Oct 2025 (RPOA investigation; NSAIDs equally effective; giant breed maturity 2-3 years); FDA CVM labeling document (long-term beyond 9 months not evaluated; cardiac NGF; primate nerve changes; cruciate exclusion)

Side effects below are drawn from the FDA’s official adverse event report, the updated Zoetis product label (January 2025), peer-reviewed literature, and veterinary clinical reports. “Common” = reported in clinical field studies; “Post-approval” = reported via post-market adverse event reporting to the FDA.

Sources: FDA CVM Dear Veterinarian Letter Dec 2024 (18 safety signals; disproportionality analysis); AVMA Feb 2025 (3,674 reports; timeline statistics); Zoetis Petcare FAQ (0.1% rate; 25M doses; clinical study common side effects); Farrell et al. Frontiers Vet Sci May 2025 (RPOA peer-reviewed); Drake Center (73% >10 years); CARE Jun 2025

Sources: FDA CVM Dear Veterinarian Letter Dec 2024; AVMA Feb 2025; Zoetis Petcare FAQ and label Jan 2025 (adverse event reporting 1-888-963-8471); FDA adverse event reporting fda.gov/reportanimalae; Seattle Veterinary Associates Dec 2025; CARE Jun 2025; Drake Center AAHA-accredited; Austin Canine Rehab Jul 2025; Charlottesville Veterinary Hospital Jan 2025; Canine Rehab OC Oct 2025; FDA CVM labeling document (long-term beyond 9 months not evaluated)

If you have concerns about your dog’s Librela treatment, a veterinary consultation is the right next step. Allow location access when prompted to find qualified veterinary resources near you.